Workshop “Diagnosis by PET-CT with 16α-[18F]-Fluoroestradiol, for hormone-dependent breast cancers”

In parallel to the Approval for the use of EstroTep obtained in July 2016, solution based on Fluoroestradiol [18F] by Cyclopharma laboratories, the Oncology Working Group of the French Society of Nuclear Medicine (SFMN) is organizing on September, Friday 23rd at Novotel Paris Montparnasse (France) a workshop dedicated to the diagnosis by PET-CT with 16α-[18F]-Fluoroestradiol, for hormone-dependent breast cancers.

This meeting will highlight the use of this new radiopharmaceutical marker for metastatic breast cancer, by combining the expertise of clinicians and nuclear doctors.